期刊文献+

TrkA、Ki-67、CD34在肾透明细胞癌中的表达及临床意义

Expressions and significances of TrkA,CD34 and Ki-67 in renal clear cell carcinoma
原文传递
导出
摘要 目的探讨神经生长因子受体络氨酸受体激酶A(TrkA)和CD34及Ki-67在肾透明细胞癌中的表达及临床意义。方法应用免疫组化方法检测48例肾透明细胞癌组织、25例正常肾脏组织中TrkA、CD34及Ki-67的表达。应用SPSS 16. 0统计软件,不同组间TrkA、CD34及Ki-67的阳性表达的比较采用交叉表χ~2检验。TrkA与CD34及Ki-67的表达的相关性用Spearman等级相关分析。结果肾透明细胞癌组和正常肾组织组中:TrkA的表达阳性率较高(83. 0%和58. 3%),两组间比较差异有统计学意义(χ~2=5. 416,P=0. 026); CD34在肾透明细胞癌组中的表达阳性率与正常肾组织组相比明显增高(39. 6. 0%和4. 2%),差异有统计学意义(χ~2=27. 422,P <0. 01); Ki-67在肾透明细胞癌组中的阳性表达率高于正常肾脏组(24. 5%和0),二者比较差异有统计学意义(χ~2=7. 083,P <0. 01)。在转移瘤及高分期肿瘤中TrkA的阳性表达与CD34及Ki-67的阳性表达具有相关性(r=0. 911、0. 548、0. 588、0. 594)。结论 TrkA在肾透明细胞癌中高表达,在高分期及转移瘤中与CD34及Ki-67的表达有相关性。联合检测TrkA、CD34及Ki-67对肾透明细胞癌诊断和预后可能有一定的临床意义。 Objective To investigate the expression and significance of the nerve growth factor receptor TrkA,CD34 and Ki-67 in renal cell carcinoma. Methods Immunohistochemistry was used to detect the expression of TrkA,CD34 and Ki-67 in 53 cases of renal cell carcinoma and 24 cases of normal kidney tissues. SPSS16. 0 statistical software was applicated to detected the differences of the expression of TrkA,Ki-67 and CD34 in different groups. Spearman rank correlation analysis was used to detect the expression of TrkA,CD34 and Ki-67. Results Compare with normal kidney group,the expression rate of TrkA in renal cell carcinoma was higher( 83. 0% and 58. 3%),and the difference was significant( χ^2=5. 416,P = 0. 026). The positive rate of CD34 expression in renal clear cell carcinoma group was significantly higher than that in normal renal tissue group( 39. 6. 0% and 4. 2%),and the difference was significant( χ^2= 27. 422,P〈0. 01); Higher Ki-67 expression was detected in the renal clear cell carcinoma group compared with that in the normal kidney group( 24. 5% and 0),there was significant difference between the two groups( χ^2= 7. 083,P〈0. 01). The positive expression of TrkA was correlated with CD34 and Ki-67 in the metastatic or high staging tumors( r = 0. 911,0. 548,0. 588,0. 594).Conclusions The high expression of TrkA in renal cell carcinoma is correlated with the high expression of CD34 and Ki-67 in the metastatic and high stages tumors. Combined detection of TrkA,CD34 and Ki-67 in renal clear cell carcinoma and may has certain significance for the diagnosis and prognosis.
作者 张新恒 单中杰 张楠 马曜辉 郭亮 Zhang Xinheng;Shan Zhongjie;Zhang Nan;Ma Yaohui;Guo Liang(Department of Urology,the Central Hospital of Sanmenxia,Sanmenxia 472000,China;The People's Hospital of Zhengzhou,Zhengzhou 450000,China)
出处 《临床医学》 CAS 2018年第10期19-22,共4页 Clinical Medicine
关键词 肾透明细胞癌 酪氨酸受体激酶A CD34 KI-67 Renal cell carcinoma Receptor tyrosine kinase-A CD34 Ki-67
  • 相关文献

参考文献5

二级参考文献57

  • 1杜贤进,张杰.分子靶向药物舒尼替尼治疗肾细胞癌[J].世界临床药物,2009,30(11):657-661. 被引量:3
  • 2刘大鹏,张勇,任宏,陈武科.siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway[J].Journal of Pharmaceutical Analysis,2007,19(1):101-106. 被引量:7
  • 3Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monocolonal antibodv reactive with a human nuclear antigen associate with cell proliferation[J]. Int J Cancer, 1983, 31(1): 13-20.
  • 4Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma [J]. J Natl Cancer Inst, 2008, 100(1): 698-711.
  • 5Liu L, Cao YC, Chen C, et al. Somfenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J]. Cancer Res, 2006, 66(24): 11851-8.
  • 6Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[ J ]. N Engl J Med, 2008, 359(4): 378-90.
  • 7Cheng AL, Kang YK, Chert Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomized double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10: 25-34.
  • 8Ryan CW,Goldman BH,Lara PJ,et al.Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma:a phase Ⅱ study of the Southwest Oncology Group[J].J Clin Oncol,2007,25:3296-3301.
  • 9Tannir NM,Zurita AI,Heymach JV.A randomized phase ii trial of sorafenib versus sorafenib plus low -dose interferon-alfa:clinical results and biomarker analysis[abstract 5093] [J].Proc Am Soc Clin Oncol,2008,26:S272.
  • 10Tomasello L,Sertoli M,Rubagotti A,et al.Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC):A phase Ⅱ study,preliminary results[J].J Clin Oncol,2008,26:16011.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部